Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral SL-172154 in CSCC and SCCHN
NCT04502888Phase 1Terminated
- Sponsor
- Shattuck Labs
- Start
- Sep 2020
- Primary completion
- Apr 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of SL-172154 in cutaneous squamous cell carcinoma (cSCC) and squamous cell carcinoma of the head and neck (HNSCC), sponsored by Shattuck Labs. Primary endpoints: Incidence of All Treatment Emergent Adverse Events and Maximum Tolerated Dose. Started Sep 2020; status: terminated.
02
Drugs
SL-172154
03
Conditions
cutaneous squamous cell carcinoma (cSCC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04502888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502888.